Treatments for gastrointestinal symptoms in acute food protein-induced enterocolitis syndrome

急性食物蛋白诱发性肠炎综合征的胃肠道症状治疗

阅读:1

Abstract

The treatment for acute food protein-induced enterocolitis syndrome (FPIES) has not been fully resolved. We investigated the efficacy of 5-HT(3) receptor inhibitors and steroids in patients with recurrent vomiting during the oral food challenge test (OFC) for acute FPIES. Patients who met the diagnostic criteria of the international guidelines of acute FPIES and developed recurrent vomiting with the OFC were enrolled. Patients who had a single vomiting underwent infusion with normal saline. A 5-HT(3) receptor inhibitor was administered intravenously when recurrent vomiting appeared with lethargy and/or pallor. If the patient continued to develop persistent symptoms, additional steroids were administered intravenously. This study examined the rate of OFCs in which the administration of a single 5HT(3) inhibitor was insufficient to improve gastrointestinal symptoms, requiring the additional administration of steroids. A total of 20 OFCs were included; 2 treated with infusion therapy, 9 OFCs treated with 5-HT(3) receptor inhibitor, and 9 OFCs treated with 5-HT(3) receptor inhibitors and steroids. Nine OFCs treated with a single 5-HT(3) receptor inhibitor were effective, with only 2 episodes of vomiting observed before administration, and none after treatment. In the remaining 9 OFCs, steroids were additionally administered due to persistent symptoms. Five of 7 OFCs with persistent vomiting improved, and all 7 OFCs with persistent lethargy improved. This study revealed that in OFCs performed due to acute FPIES leading to recurrent vomiting, monotherapy with 5-HT(3) receptor inhibitors was insufficient in half of the OFCs, suggesting that combination therapy with 5-HT(3) receptor inhibitors and steroids should be considered for severe OFCs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。